消息

In the elderly diffuse large B‑cell lymphoma (DLBCL) population, two separate studies highlighted epcoritamab’s activity. The Phase 2 EPCORE DLBCL‑3 trial reported a 67 % overall response rate and a 58 % complete response rate, with a safety profile in line with expectations. The Phase 1b/2 EPCORE NHL‑2 trial achieved a 93 % overall response rate a...

全文

Genmab’s most recent clinical data reinforce the therapeutic promise of epcoritamab. A post‑hoc subgroup analysis of the Phase 3 EPCORE FL‑1 trial showed that epcoritamab combined with rituximab and lenalidomide (R2) delivers a consistently reduced risk of disease progression or death, with hazard ratios below 0.3 across all FLIPI scores (0–2 and 3...

全文

Orbis Investment Management Limited announced on 12 June 2026 that it now controls 3,112,476 voting shares in Genmab A/S, representing 4.99 % of the company’s share capital. The notification, filed under Section 30 of the Danish Capital Markets Act, is likely to influence investor sentiment and market perception but does not alter Genmab’s operatio...

全文

In sum, the $600 million investment by Sixth Street provides CRK with a stronger balance sheet, reduced fixed charges, and a larger ownership share in Pinnacle, while the company’s financial performance highlights challenges in revenue growth, profitability, and cash generation.

全文

Market sentiment has remained mixed. Over the past six months, CRK’s stock price fell 37.5 % to trade at $13.30 per share. The company’s long‑term revenue growth has been modest, with a 5.7 % compounded annual growth rate over the last five years, below industry benchmarks. Adjusted EBITDA margin declined by 6.1 percentage points to 72.2 % for the...

全文

The sale, reported on 15 June 2026, is seen as a validation of CRK’s Western Haynesville acreage and the potential for future natural gas production growth. It also improves CRK’s financial position by eliminating preferred equity and debt, thereby freeing working capital and simplifying the capital structure. The deal highlights the value of CRK’s...

全文

Comstock Resources (CRK) announced a $600 million strategic investment by Sixth Street in its midstream subsidiary Pinnacle Gas Services (Pinnacle). The transaction values Pinnacle at an enterprise value of $2.2 billion and involves Sixth Street acquiring a 27 % non‑controlling common equity interest. CRK retains a 73 % controlling stake and will c...

全文

Overall, Adaptive is positioning its MRD diagnostics unit for continued growth and preparing for a potential standalone entity, while leveraging a sizable convertible debt issuance to finance debt repayment, share repurchases, and further MRD expansion. The company’s focus on AI‑driven discovery in Immune Medicine and the strategic separation refle...

全文

The announcements prompted a 9 % decline in Adaptive’s shares in pre‑market trading. Despite the split and financing, the company stresses that no assurance exists that the separation will result in a transaction or any specific outcome. The convertible notes’ terms remain to be finalized at pricing, but the structure aims to limit potential equity...

全文

Concurrently, Adaptive disclosed a private placement of $250 million in senior convertible notes due 2031. Net proceeds will be used to repay the outstanding OrbiMed Purchase Agreement, repurchase up to $25 million of common shares via capped call transactions, and fund general corporate purposes and opportunistic initiatives in the MRD business. T...

全文